May 30, 2018

Bioanalysis explores novel LC-MS assays impacting CYP and transporter DDI evaluations

Bioanalysis, a leading MEDLINE indexed journal for bioanalytical scientists, has published a Special Focus Issue on LC–MS assays impacting CYP and transporter DDI evaluations. The journal is published by Future Science Group.


The Special Focus Issue, guest Edited by Ragu Ramanathan (Pfizer), explores novel LC–MS assays impacting CYP and transporter DDI evaluations, through original research articles, as well as expert perspectives in the form of commentary-style articles.


The issue discusses new technologies in MS as well as looking into multiplexing, and getting more information using HRMS, as well as sample pooling approaches. Proposals of several endogenous biomarkers for evaluating DDI at early stages in clinical trials, so DDI studies do not need to be continued into the latter stages, are also explored.


“There is a growing interest in exploring novel LC–MS/MS, LC-high resolution accurate MS (LC–HRMS), or LC–MS/HRMS assays early in drug development to ensure DDI related liabilities to establish safety and efficacy of a NCE.  This special issue brings together some the novel LC–MS applications and outlook from leaders in the field” said Ragu Ramanathan (Pfizer).


“I am delighted to have worked with experts in the field to produce this Special Focus Issue, which appears to demonstrate the expansion of interest in using sensitive and selective LC–MS assays for evaluations of DDI potentials early in development of new chemical entities to assure safety and efficacy.” commented Sankeetha Nadarajah (Managing Commissioning Editor, Bioanalysis).


To read the full issue, please visit


The guest editors’ free-access foreword article is available online here:


About Bioanalysis


Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.


About Bioanalysis Zone


Since launching in 2011, Bioanalysis Zone has attracted over 7,500 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews and commentaries. Membership is completely free of charge. Sign up online at:



About Future Science Group


Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.


The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.


© 2019 Future Science Group

Unitec House, 2 Albert Place,

London, N3 1QB, UK

Tel: +44 (0)20 8371 6090

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle